Trial
NCT00083759
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Biogen
Collaborators
Elan Pharmaceuticals
Condition
Rheumatoid Arthritis
Intervention
natalizumab
Why stopped
The biological effect seen with natalizumab was not sufficient to warrant further development in RA.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-07-18